Efficacy and Safety of Twice-Daily Glycopyrrolate Versus Placebo in Patients With COPD: The GEM2 Study

Long-acting bronchodilators including muscarinic antagonists are central to the management of patients with COPD. The Glycopyrrolate Effect on syMptoms and lung function (GEM2) study assessed the efficacy and safety of twice-daily glycopyrrolate 15.6 μg in patients with moderate-to-severe airflow li...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Chronic Obstr Pulm Dis
Main Authors: Kerwin, Edward, Siler, Thomas M., Korenblat, Phillip, White, Alexander, Eckert, Joerg H., Henley, Michelle, Patalano, Francesco, D’Andrea, Peter
Formato: Artigo
Idioma:Inglês
Publicado: COPD Foundation Inc 2016
Assuntos:
Original Research
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5559157/
https://ncbi.nlm.nih.gov/pubmed/28848879
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.15326/jcopdf.3.2.2015.0157
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares